Literature DB >> 1415759

Ischemic preconditioning protects against infarction in rat heart.

Y Liu1, J M Downey.   

Abstract

We examined the anti-infarct effect of ischemic preconditioning in the rat heart. All hearts were subjected to 30 min of regional coronary ischemia and 2 h of reperfusion. Infarct size was determined by tetrazolium. The control group had an average infarct size of 31% of the risk zone. Three 5-min cycles of preconditioning ischemia limited the infarct size to 3.7%. Neither the adenosine receptor blocker PD 115,199 nor the ATP-sensitive potassium channel blocker, glibenclamide, could block this protection. Intracoronary adenosine A1-receptor agonist 2-chloro-N6-cyclopentyladenosine offered a significant anti-infarct protection to the isolated rat heart, however. Although one 5-min cycle of preconditioning did not protect the rat heart from infarction (31% infarction in risk zone), it did attenuate arrhythmias. We conclude that 1) the rat heart can be preconditioned, which argues against mitochondrial adenosinetriphosphatase being the mechanism of preconditioning; 2) the threshold for preconditioning is higher in rat than rabbit or dog; 3) a role for adenosine in preconditioning was only partially supported; and 4) a role for ATP-sensitive potassium channels was not supported.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415759     DOI: 10.1152/ajpheart.1992.263.4.H1107

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  62 in total

Review 1.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Apoptosis in myocardial ischaemia and infarction.

Authors:  P A J Krijnen; R Nijmeijer; C J L M Meijer; C A Visser; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

3.  Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response.

Authors:  A Clerk; J Gillespie-Brown; S J Fuller; P H Sugden
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

Review 4.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

5.  Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel.

Authors:  K Yabe; Y Nasa; S Takeo
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

6.  Protein kinase Cepsilon mediates salutary effects on electrical coupling induced by ischemic preconditioning.

Authors:  Thomas J Hund; Deborah L Lerner; Kathryn A Yamada; Richard B Schuessler; Jeffrey E Saffitz
Journal:  Heart Rhythm       Date:  2007-06-08       Impact factor: 6.343

7.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

8.  Involvement of ATP-sensitive potassium channels in preconditioning protection.

Authors:  S Rohmann; H Weygandt; P Schelling; L Kie Soei; P D Verdouw; I Lues
Journal:  Basic Res Cardiol       Date:  1994 Nov-Dec       Impact factor: 17.165

Review 9.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

10.  The impact of sex and myocardial ischemic preconditioning on immunohistochemical markers of acute myocardial infarction.

Authors:  K Scholl; R Huhn; St Ritz-Timme; F Mayer
Journal:  Int J Legal Med       Date:  2018-10-23       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.